Rechallenge with Anti-PD-1 Inhibitors in Patients with Recurrent Gynecologic Malignancies.

Migang Kim,Chi-Son Chang,Min Chul Choi,Jeong-Won Lee,Hyun Park,Won Duk Joo

Yonsei medical journal（2023）

引用 0|浏览3

暂无评分

摘要

These results suggest that responses to ICI rechallenge are not as intolerable as responses to previous ICI. Clinicians should carefully consider rechallenge with PD-1 inhibitors outside of clinical trials until there are sufficient data to routinely support this practice.

查看译文

关键词

inhibitors

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要